Lexaria Bioscience (LEXX) Change in Cash (2010 - 2026)

Lexaria Bioscience has reported Change in Cash for 17 years, with the latest figure at -$1.7 million in Q2 2026.

• Quarterly Change in Cash rose 11.93% year-over-year to -$1.7 million in Q2 2026, while the trailing twelve-month figure through May 2026 was -$1.1 million (up 71.12% YoY) and the FY2025 annual result came in at -$4.7 million, down 191.26% from the prior year.
• Change in Cash slipped to -$1.7 million in Q2 2026 per LEXX's latest filing, from $846908.0 in the prior quarter.
• Over five years, Change in Cash peaked at $3.8 million in Q2 2024 and troughed at -$2.8 million in Q3 2025.
• A 5-year average of -$344848.2 and a median of -$1.3 million in 2022 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2024 and 2025: Change in Cash surged 3569.34% in 2024, then plunged 158.49% in 2025.
• Over 5 years, Change in Cash stood at -$1.3 million in 2022, then jumped by 147.03% to $602063.0 in 2023, then jumped by 162.16% to $1.6 million in 2024, then jumped by 57.07% to $2.5 million in 2025, then sank by 166.68% to -$1.7 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$1.7 million, $846908.0, and $2.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.